4th Department of Medicine Haematology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Clinical Development Department Joint stock Company BIOCAD Saint Petersburg Russia

Dana Farber Cancer Institute Harvard Medical School Boston MA

Department of Biology and Ecology University of Ostrava Ostrava Czech Republic

Department of Clinical Hematology University Hospital Brno Brno Czech Republic

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Hemato Oncology Charles University Hospital Pilsen Pilsen Czech Republic

Department of Hematology and Transfusiology University Hospital Bratislava Bratislava Slovakia

Department of Hematooncology University Hospital and Palacky University Olomouc Olomouc Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic; and

Faculty of Medicine University of Ostrava Ostrava Czech Republic

Institute of Quantitative Biology Biochemistry and Biotechnology University of Edinburgh Edinburgh United Kingdom

Zobrazit více v PubMed

Munshi NC, Avet-Loiseau H, Rawstron AC, et al. . Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1): 28-35. PubMed PMC

Miething CC. Clonal evolution in myeloma: a narrow road to remission. Haematologica. 2019;104(7):1292-1293. PubMed PMC

Walker BA, Boyle EM, Wardell CP, et al. . Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911-3920. PubMed PMC

Lohr JG, Stojanov P, Carter SL, et al. ; Multiple Myeloma Research Consortium . Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1): 91-101. PubMed PMC

Bolli N, Avet-Loiseau H, Wedge DC, et al. . Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5(1):1-13. PubMed PMC

Walker BA, Mavrommatis K, Wardell CP, et al. . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma [published correction appears in Blood. 2018;132(13):1461]. Blood. 2018;132(6):587-597. PubMed PMC

Kortüm KM, Mai EK, Hanafiah NH, et al. . Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226-1233. PubMed PMC

Campbell PJ, Getz G, Korbel JO, et al. ; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium . Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82-93. PubMed PMC

Goicoechea I, Puig N, Cedena MT, et al. . Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021;137(1):49-60. PubMed

van Dongen JJM, Lhermitte L, Böttcher S, et al. ; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708) . EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975. PubMed PMC

Sekine H, Okazaki K, Kato K, et al. . O-GlcNAcylation signal mediates proteasome inhibitor resistance in cancer cells by stabilizing NRF1. Mol Cell Biol. 2018;38(17):e00252-18. PubMed PMC

Tiwari A, Pattnaik N, Mohanty Jaiswal A, Dixit M. Increased FSHD region gene1 expression reduces in vitro cell migration, invasion, and angiogenesis, ex vivo supported by reduced expression in tumors. Biosci Rep. 2017;37(5):BSR20171062. PubMed PMC

Tiwari A, Mukherjee B, Hassan MK, Pattanaik N, Jaiswal AM, Dixit M. Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion. BMC Cancer. 2019;19(1):1–15. PubMed PMC

Velmurugan BK, Yeh K-T, Hsieh M-J, et al. . UNC13C suppress tumor progression via inhibiting EMT pathway and improves survival in oral squamous cell carcinoma. Front Oncol. 2019;9(AUG):1–6. PubMed PMC

Scrivens PJ, Noueihed B, Shahrzad N, Hul S, Brunet S, Sacher M. C4orf41 and TTC-15 are mammalian TRAPP components with a role at an early stage in ER-to-Golgi trafficking. Mol Biol Cell. 2011;22(12):2083-2093. PubMed PMC

Grossman RL, Heath AP, Ferretti V, et al. . Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375(12): 1109-1112. PubMed PMC

Ziccheddu B, Biancon G, Bagnoli F, et al. . Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv. 2020;4(5):830-844. PubMed PMC

Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Vol 28.; 2000. http://www.genome.ad.jp/kegg/. Accessed July 8, 2020. PubMed PMC

Tanaka K. The proteasome: overview of structure and functions. Proc Jpn Acad, Ser B, Phys Biol Sci. 2009;85(1):12-36. PubMed PMC

Zhu YX, Braggio E, Shi CX, et al. . Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536-545. PubMed PMC

Shirazi F, Jones RJ, Singh RK, et al. . Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. Proc Natl Acad Sci USA. 2020;117(33):20004-20014. PubMed PMC

Cotto KC, Wagner AH, Feng Y-Y, et al. . DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018;46(D1):D1068-D1073. PubMed PMC

Chakravarty D, Gao J, Phillips SM, et al. . OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017(1):1-16. PubMed PMC

Shi C-X, Kortüm KM, Zhu YX, et al. . CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for Bortezomib sensitivity in multiple myeloma. Mol Cancer Ther. 2017;16(12):2862-2870. PubMed PMC